Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.
MetadataShow full item record
The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.
Gastrointestinal Cancers Clinical Trials
License start date
OncoTargets and therapy, 2016, 9 pp. 7235 - 7245